运用度拉糖肽联合吡格列酮治疗2型糖尿病合并非酒精性脂肪肝的效果分析  

Analysis of the Effect of Dulaglutide Combined with Pioglitazone in the Treatment of Type 2 Diabetes Mellitus Complicated with Non-alcoholic Fatty Liver

作　　者：徐蕾[1] 李达[1] XU Lei;LI Da(Department of Endocrinology and Nephrology,Jilin Integrated Traditional Chinese and Western Medicine Hospital,Jilin Province,Jilin 132000,Jilin,China)

机构地区：[1]吉林省吉林中西医结合医院内分泌肾病科,吉林吉林132000

出　　处：《系统医学》2025年第4期99-102,共4页Systems Medicine

摘　　要：目的研究2型糖尿病合并非酒精性脂肪肝患者运用度拉糖肽联合吡格列酮治疗的临床效果。方法非随机选取2021年8月—2023年8月吉林省吉林中西医结合医院收治的68例2型糖尿病合并非酒精性脂肪肝患者为研究对象。根据治疗方法不同分组,对比组34例患者运用吡格列酮治疗,观察组34例患者运用度拉糖肽联合吡格列酮治疗。对比分析两组的对比分析两组的血糖情况、肝功能状况及疗效。结果治疗后,观察组的空腹血糖为(4.77±0.52)mmol/L、餐后2 h血糖为(6.98±1.23)mmol/L、糖化血红蛋白为(6.04±0.50)%,低于对比组的(5.63±1.01)mmol/L、(8.05±1.34)mmol/L、(7.11±0.95)%,差异有统计学意义(t=4.414、3.430、5.811,P均<0.05);观察组的肝功能状况优于对比组,差异有统计学意义(P均<0.05);观察组的疗效高于对比组,差异有统计学意义(P<0.05)。结论运用度拉糖肽联合吡格列酮治疗,可以使患者的空腹血糖得到有效控制,同时还可改善糖化血红蛋白,提高疗效,改善肝功能。Objective To study the clinical effect of dirageptide and pioglitazone in patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver.Methods From August 2021 to August 2023,sixty-eight patients with type 2 diabetes mellitus complicated with nonalcoholic fatty liver treated in Jilin Integrated Traditional Chinese and Western Medicine Hospital in Jilin Province were non-randomly selected as the research objects.They were grouped according to different treatment,thirty-four patients in the control group were treated with pioglitazone,and thirty-four patients in the observation group were treated with duragantide and pioglitazone.The blood glucose,liver function and efficacy of the two groups were compared and analyzed.Results After treatment,the fasting blood glucose(4.77±0.52)mmol/L,postprandial 2 h blood glucose(6.98±1.23)mmol/L,glycated hemoglobin(6.04±0.50)%in the observation group were lower than(5.63±1.01)mmol/L,(8.05±1.34)mmol/L,(7.11±0.95)%in the control group,and the differences were statistically significant(t=4.414,3.430,5.811,all P<0.05).The liver function of the observation group was better than that of the control group,and the differences were statistically significant(all P<0.05).The treatment effectiveness of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Conclusion The application of dulaglutide combined with pioglitazone in the treatment of patients can effectively control the fasting blood glucose,at the same time,it can also improve glycated hemoglobin,improve the effectiveness of treatment,and improve liver function.

关 键 词：度拉糖肽 吡格列酮 2型糖尿病 非酒精性脂肪肝 

分 类 号：R587[医药卫生—内分泌]